Skip to main content

Table 1 Results from cell and cell tumour experiments

From: Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo

Cell line

IC50 (mean ± SEM)

Tumour growth inhibition in vivo by R115777

Ras statusa

ERa

EGFRa

HER2a

  

50 mg/kg

100 mg/kg

    

SK-BR3

39.0 ± 25.8 nmol/l

-

-

Wild-type

-

+

++

MCF-7

46.0 ± 5.0 nmol/l

-

-

Wild-type, over-expression of n-ras

++

+

(+)

MCF-7/HER2-18

60.3 ± 117 nmol/l

80.8%

95.9%

Wild-type, over-expression of n-ras

++

+

+++

BT474

195 ± 119 nmol/l

-

-

Wild-type

+

-

++

SKOV3

2.7 ± 0.4 μmol/l

60.1%

20.4%

Wild-type

-

++

+++

MDA-MB231

5.9 ± 0.8 μmol/l

-68.8%

-91.2%

Mutated k-ras

-

+++

+

  1. The table shows the concentration of R115777 required to reduce cell numbers by 50% (50% inhibitory concentration [IC50]), inhibition by R115777 at two different doses in tumours grown in athymic mice, and receptor and ras status for the different cancer cell lines. aData collected from the literature [4,12,46]. EGFR, epidermal growth factor receptor; ER, oestrogen receptor; SEM, standard error of the mean.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us